))
Bright Minds Biosciences & Next Generation Psychedelics
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on October 16, 2023 23:24 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337249293 series 3380517
Innehåll tillhandahållet av Encode Ideas, L.P., Encode Ideas, and L.P.. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Encode Ideas, L.P., Encode Ideas, and L.P. eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug development. We cover Bright Minds pipeline of 5HT2 agonists, the importance of FDA's approval of Spravato, and Compass's impending Ph2b psilocybin data, among other topics relevant in the psychedelic space.
Companies discussed during the podcast:
- Bright Minds Biosciences Inc. (CSE: DRUG/OTCQB: BMBIF)
- Compass Pathways plc (Nasdaq: CMPS)
- Cybin Inc. (NYSE: CYBN)
- Xenon Pharmaceuticals Inc. (Nasdaq: XENE)
- Johnson & Johnson (NYSE: JNJ)
7 episoder
Dela
